Использованные источники

1. Al-Tawfiq J. A., Memish Z. A. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) // Expert review of anti-infective therapy. 2017. 15. № 3.

С. 269-275.

2. Assiri A. et al. Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia // Clin Infect Dis. 2016. № 63. pp. 951-953

3. Alserehi H. et al. Impact of Middle East respiratory syndrome coronavirus (MERS- CoV) on pregnancy and perinatal outcome // BMC Infect Dis. 2016. №16, p. 105

4. Baig A.M. et al..Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020. doi:10.1021/acschemneuro.0c00122.

5. Bassetti M. The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm https://doi.org/10.1111/eci.13209 URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13209

6. Behzadi M.A., Leyva-Grado V.H. Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections // Frontiers in microbiology. 2019. № 10. p. 1327.

7. Canada.ca. 2019 novel coronavirus: Symptoms and treatment The official website of the Government of Canada URL: https://www.canada.ca/en/public-health/services/diseases/2019- novel-coronavirusinfection/symptoms.html

8. CDC. 2019 Novel Coronavirus URL: https://www.cdc.gov/coronavirus/2019- ncov/index.html

9. Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. doi: 10.1016/S0140- 6736(20)30211-7

10. Chong Y.P. et al. Antiviral Treatment Guidelines for Middle East Respiratory Syndrome // Infection & chemotherapy. 2015. 47. № 3. pp. 212-222.

11. Cinatl J. et al. Treatment of SARS with human interferons // Lancet. 2003. 362. № 9380. pp. 293-294.

12. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: Interim Guidance. Updated 2 July 2015. WHO/MERS/Clinical/15.1

13. Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 International Journal of Antimicrobial Agents 2020.

14. Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care .

15. Commonwealth of Australia | Department of Health. Novel coronavirus (2019-nCoV) URL: https://www.health.gov.au/health-topics/novel-coronavirus-2019-ncov

16. Corman V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR //Eurosurveillance. - 2020. - Т. 25. - №. 3. - 25(3). doi: 10.2807/1560-7917.ES

17. Coronavirus.URL: https://multimedia.scmp.com/widgets/china/wuhanvirus/?fbclid=IwAR2hDHzpZEh5Nj3

60i2O%201ES 78rXRFymAaFaUK6ZG4m0UTCV1xozulxX1jio

18. Dayer M.R. et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study // Arch Clin Infect Dis. 2017 ; 12(4):e13823. doi: 10.5812/archcid.13823

19. Dyall J. et al. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current

Therapeutic Options and Potential Targets for Novel Therapies // Drugs. 2017. 77. № 18. С.1935-1966.

20. European Commission. Novel coronavirus 2019-nCoV URL: https://ec.europa.eu/health/coronavirus_en

21. FDA. Novel coronavirus (2019-nCoV) URL: https://www.fda.gov/emergency- preparedness-andresponse/mcm-issues/novel-coronavirus-2019-ncov

22. Federal Ministry of Health. Current information on

the coronavirus URL:



Gao, J., Tian, Z., & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 2020.

24. Gorbalenya A.E.et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses

- a statement of the Coronavirus Study Group, 2020. doi: https://doi.org/10.1101/2020.02.07.937862

25. Hart B.J. et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays // The Journal of general virology. 2014. 95. Pt 3. С. 571-577.

26. Huang C. et al. Cinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5. [Epub ahead of print]

27. Ji W. et al. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human //Journal of Medical Virology. - 2020.

28. Jeong S.Y. et al. MERS-CoV Infection in a Pregnant Woman in Korea. J Korean Med Sci. 2017 Oct;32(10):1717-1720. doi: 10.3346/jkms.2017.32.10.1717.

29. Junqiang L. et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV)

Pneumonia https://doi.org/10.1148/radiol.2020200236 URL:


30. Le Chang et al. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine Reviews 2020. doi:10.1016/j.tmrv.2020.02.003.

31. Li Q et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus- Infected Pneumonia N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316

32. Li X et al. Potential of large 'first generation' human-to-human transmission of 2019- nCoV. J Med Virol. 2020 Jan 30. doi: 10.1002/jmv.25693. [Epub ahead of print]

33. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020 Jan 28. doi: 10.5582/bst.2020.01020. [Epub ahead of print]

34. Mandell L.A.

et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults //Clinical infectious diseases. - 2007. - Т. 44. - №. Supplement_2. - pp. S27-S72.

35. Mao L. et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in

Wuhan, China: A retrospective case series study; 2020. doi:


36. Ministere des Solidaritds et de la SantdCoronavirus : questions-reponses URL: https://solidaritessante.gouv.fr/soins-et-maladies/maladies/maladies- infectieuses/coronavirus/coronavirus-questionsreponses

37. Mo Y., Fisher D.A. review of treatment modalities for Middle East Respiratory Syndrome // The Journal of antimicrobial chemotherapy. 2016. 71. № 12. pp. 3340-3350.

38. Momattin H. et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-

-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013 Oct;17(10):e7928

39. National Health Commission of the People's Republic of China. URL: http://en.nhc.gov.cn

40. Netland J. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2. J Virol. 2008;82:7264-75.


41. NHS. Coronavirus (2019-nCoV) URL: https://www.nhs.uk/conditions/wuhan-novel- coronavirus/

42. Omrani A.S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study //The Lancet Infectious Diseases. 2014. Т. 14. №. 11. pp. 1090-1095.

43. Outbreak of acute respiratory syndrome associated with a novel coronavirus, China: first local transmission in the EU/EEA - third update URL:

https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-risk- assessment-china-31january-2020_0.pdf

44. Park M.H. et al. Emergency cesarean section in an epidemic of the Middle East respiratory syndrome: a case report Korean J Anesthesiol, 69 (2016), pp. 287-291, doi: 10.4097/kjae.2016.69.3.287

45. Phan L. T. et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam //New England Journal of Medicine. - 2020.

46. Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV). URL: https://nextstrain.org/groups/blab/sars-like-cov

47. Public Health England. Investigation and initial clinical management of possible cases

of novel coronavirus (2019-nCoV) infection URL:

https://www.gov.uk/government/publications/wuhan-novelcoronavirus-initial-investigation-of- possible-cases/investigation-and-initial-clinical-management-ofpossible-cases-of-wuhan-novel- coronavirus-wn-cov-infection

48. Royal Pharmaceutical Society of Great Britain Trading as Royal Pharmaceutical Society. Wuhan novel coronavirus URL: https://www.rpharms.com/resources/pharmacy- guides/wuhan-novel-coronavirus

49. The State Council The People's Republic Of China URL: http://english.www.gov.cn/

50. The Centers for Disease Control and Prevention (CDC). Interim guidance for healthcare professionals on human infections with 2019 novel coronavirus (2019- nCoV). URL: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

51. Touret, F., & de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Research, 104762.

52. Upchurch C.P. et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes //Chest. - 2018. - Т. 153. - №. 3. - pp. 601-610.

53. Wang Z. et al. Clinical characteristics and therapeutic procedure for four cases with

2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020. doi:10.5582/bst.2020.01030.

54. World health organization. Managing Ethical Issues in Infectious Disease Outbreaks. Publication date: 2016. URL: https://www.who.int/ethics/publications/infectious-disease- outbreaks/en/

55. Wu P. et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020 //Eurosurveillance. 2020. Т. 25. №.3. doi: 10.2807/1560-7917.ES.2020.25.3.2000044

56. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China:. J Med Virol 2020. doi:10.1002/jmv.25707.

57. Zhang J. et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med 2020. doi:10.1016/S2213-2600(20)30071-0.

58. Zumla A. et al. Coronaviruses - drug discovery and therapeutic options // Nature reviews. Drug discovery. 2016. 15. № 5. С. 327-347.

59. China CDC.Diagnosis and treatment protocolfor COVID-19 patients (trial version 7, revised)

60. Портал непрерывного медицинского и фармацевтического образования Минздрава России URL: https://nmfo-vo.edu.rosminzdrav.ru/#/user-account/view-iom/e8b1f2ca-6be5-9125-4a1e

61. Всемирная организация здравоохранения. Временное руководство по рациональному использованию средств индивидуальной защиты от коронавирусной болезни (COVID-19): 19 марта 2020 г. URL: https://apps.who.int/iris/handle/10665/331498.

62. Всемирная организация здравоохранения. Клиническое руководство по ведению пациентов с тяжелой острой респираторной инфекцией при подозрении на инфицирование новым коронавирусом (2019-nCoV). Временные рекомендации. Дата публикации: 25 января

2020 г. URL:

http://www.euro.who.int/____ data/assets/pdf_file/0020/426206/RUS-Clinical-Management-

ofNovel_CoV_Final_without-watermark.pdf?ua= 1.

63. Всемирная организация здравоохранения. Клиническое руководство по ведению пациентов с тяжелыми острыми респираторными инфекциями при подозрении на инфицирование БВРС-КоВ.

Временные рекомендации. Дата публикации: Июль 2015 г. URL:


64. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. О новой коронавирусной инфекции. URL: https://rospotrebnadzor.ru/region/korono_virus/punkt.php 65. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Методические рекомендации МР 3.1.0140-18 «Неспецифическая профилактика гриппа и других острых респираторных инфекций».

65. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar 27. doi: 10.1111/jth.14817.

66. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China.

67. Gautret F., Lagier J-C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an openlabel non-randomized clinical trial. International Journal of Antimicrobial Agents

68. In Press 17 March 2020 -DOI : 10.1016/j.ijantimicag.2020.105949

69. Кузьменков А.Ю., Трушин И.В., Авраменко А.А., Эйдельштейн М.В., Дехнич

А.В., Козлов Р.С. AMRmap: Интернет-платформа мониторинга

антибиотикорезистентности. Клиническая микробиология и антимикробная химиотерапия. 2017;19(2):84-90.

70. Carmeli Y. et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999 May 24;159(10):1127-32.

71. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4a3c02bc-a256-48f2- 90a8-14b48b7d197c&t=

72. Распоряжение Правительства РФ от 12 октября 2019 г. № 2406-р «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2020 год...»

73. Pogue J., Kaye K., Veve M., et al. "Real World" treatment of multi-drug resistant (MDR) or extensively-drug resistant (XDR) P. aeruginosa infections with ceftolozane/tazobactam (C/T) versus a polymyxin or aminoglycoside (Poly/AG) based regimen: a multicenter comparative effectiveness study. Proceedings of the IDweek 2018, October 3-7, San Francisco, USA. Poster/Abstract 2406.

74. Xiao A., et al J Clin Pharm. 2016; 56(1): 56-66; Luzelena Caro, David P. Nicolau, Jan J. De Waele et al. Lung penetration, bronchopulmonary pharmacokinetic/ pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy, dkaa049, https://doi.org/10.1093/jac/dkaa049 Published: 24 March 2020

75. Tommaso Lupia*, Silvia Scabini, Simone Mornese Pinna, Giovanni Di Perri, Francesco Giuseppe De Rosa, Silvia Corcione «2019 novel coronavirus (2019-nCoV) outbreak: A new challenge», Journal of Global Antimicrobial Resistance 21 (2020) 22-27

76. https://www.vmeda.org/wp-content/uploads/2020/03/koronavirus-metod-rekomendaczii.pdf

77. Lupia T. et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge Journal of Global Antimicrobial Resistance Volume 21, June 2020, Pages 22-27

78. Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019- novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2020 Mar 6. doi: 10.1097/CM9.0000000000000797

79. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi: 10.1016/j.ijantimicag.2020.105938.

80. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults https://doi.org/10.1111/apa.15270

<< | >>

Еще по теме Использованные источники:

  1. Список использованных источников и литературы
  5. Список использованных источников и литературы
  14. Использованные нормативные и методические документы
  15. Источники ТЭЛА
  16. Источники возбудителей
  17. Источник инфекции